Michael J. LaBarre served as Senior Vice President, Chief Technical Officer of Halozyme Therapeutics. On March 17, 2025, he notified the Company of his decision to retire, effective March 17, 2025, after many years of service and contributions to the Company's ENHANZE drug delivery technology.